BRIACELL THERAPEUTICS CORP. Operating Cash Flow
BRIACELL THERAPEUTICS CORP. (BCTX) reported Operating Cash Flow of -$22.69 million for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) operating activities for the quarter ending 2026-04-30 was -$7.02M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) operating activities for the quarter ending 2026-01-31 was -$7.97M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) operating activities for the quarter ending 2025-10-31 was -$7.70M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) operating activities for the quarter ending 2025-07-31 was -$8.13M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) operating activities for fiscal 2025 was -$28.17M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) operating activities for fiscal 2024 was -$24.13M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) operating activities for fiscal 2023 was -$23.74M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) operating activities for fiscal 2022 was -$12.48M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-04-30 | -$7.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | -$14.99M derived: sum of 2 quarters · filed 2026-06-09 | -$22.69M 10-Q · filed 2026-06-09 | -$30.82M derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | -$7.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | -$15.67M 10-Q · filed 2026-03-10 | -$23.80M derived: sum of 3 quarters · filed 2026-03-10 | -$30.97M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | -$7.70M 10-Q · filed 2025-12-11 | -$15.84M derived: sum of 2 quarters · filed 2025-12-11 | -$23.00M derived: sum of 3 quarters · filed 2026-06-09 | -$28.92M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | -$8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$15.30M derived: sum of 2 quarters · filed 2026-06-09 | -$21.22M derived: sum of 3 quarters · filed 2026-06-09 | -$28.17M 10-K · filed 2025-10-16 |
| 2025-04-30 | -$7.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | -$13.08M derived: sum of 2 quarters · filed 2026-06-09 | -$20.04M 10-Q · filed 2026-06-09 | -$24.07M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | -$5.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | -$12.88M 10-Q · filed 2026-03-10 | -$16.91M derived: sum of 3 quarters · filed 2026-03-10 | -$21.99M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | -$6.96M 10-Q · filed 2025-12-11 | -$10.99M derived: sum of 2 quarters · filed 2025-12-11 | -$16.07M derived: sum of 3 quarters · filed 2025-12-11 | -$23.48M derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | -$4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$9.12M derived: sum of 2 quarters · filed 2025-10-16 | -$16.52M derived: sum of 3 quarters · filed 2025-10-16 | -$24.13M 10-K · filed 2025-10-16 |
| 2024-04-30 | -$5.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-16 | -$12.49M derived: sum of 2 quarters · filed 2025-06-16 | -$20.09M 10-Q · filed 2025-06-16 | -$31.01M derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | -$7.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-12 | -$15.01M 10-Q · filed 2025-03-12 | -$25.93M derived: sum of 3 quarters · filed 2025-03-12 | -$31.26M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | -$7.61M 10-Q · filed 2024-12-16 | -$18.52M derived: sum of 2 quarters · filed 2024-12-16 | -$23.86M derived: sum of 3 quarters · filed 2024-12-16 | -$27.81M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | -$10.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | -$16.25M derived: sum of 2 quarters · filed 2024-10-29 | -$20.20M derived: sum of 3 quarters · filed 2024-10-29 | -$23.74M 10-K · filed 2024-10-29 |
| 2023-04-30 | -$5.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | -$9.28M derived: sum of 2 quarters · filed 2024-06-14 | -$12.83M 10-Q · filed 2024-06-14 | -$16.15M derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | -$3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-18 | -$7.49M 10-Q · filed 2024-03-18 | -$10.82M derived: sum of 3 quarters · filed 2024-03-18 | -$15.64M derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | -$3.54M 10-Q · filed 2023-12-14 | -$6.87M derived: sum of 2 quarters · filed 2023-12-14 | -$11.69M derived: sum of 3 quarters · filed 2023-12-14 | -$14.25M derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | -$8.15M derived: sum of 2 quarters · filed 2023-10-25 | -$10.71M derived: sum of 3 quarters · filed 2023-10-25 | -$12.48M 10-K · filed 2023-10-25 |
| 2022-04-30 | -$4.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | -$7.38M derived: sum of 2 quarters · filed 2023-06-14 | -$9.16M 10-Q · filed 2023-06-14 | |
| 2022-01-31 | -$2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-16 | -$4.33M 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | -$1.78M 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | -$7.75M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |